Hospital
Holmes Regional Medical Center, INC.
Holmes Regional Medical Center, INC. was paid $12.33M by Medicaid between Jan 2018 and Dec 2024, across 206 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoHOLMES REGIONAL MEDICAL CENTER, INC.
MELBOURNE, FL 32901
MELBOURNE, FL 32901
33aNPI1295702728assigned 03/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.33M
24GClaims613,231
24DCodes billed206
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#42 of 163
Median peer was paid$4.77M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PULIO, KRISTEN controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,655 | $700K | |
| 2019 | 133,469 | $1.92M | |
| 2020 | 106,652 | $1.36M | |
| 2021 | 123,321 | $2.03M | |
| 2022 | 123,703 | $2.95M | |
| 2023 | 57,193 | $2.25M | |
| 2024incomplete | 20,238 | $1.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 34,412 | 29,975 | $3.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 30,105 | 27,650 | $2.90M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 17,080 | 14,645 | $1.64M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 5,184 | 4,833 | $456K |
| 36415 | Collection of venous blood by venipuncture | 3.4% | 29,476 | 20,849 | $419K |
| 80053 | Comprehensive metabolic panel | 2.5% | 36,486 | 29,213 | $305K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 3,397 | 3,062 | $214K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 5,825 | 4,883 | $194K |
| 87400 | 1.3% | 4,223 | 3,829 | $166K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 2,071 | 1,858 | $151K |
| 87430 | <1% | 2,754 | 2,649 | $123K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,418 | 804 | $122K |
194 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,766 | $113K |
| 87486 | <1% | 8,765 | $110K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 9,540 | $102K |
| 99218 | <1% | 4,712 | $84K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 920 | $84K |
| 87088 | <1% | 8,601 | $83K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,610 | $82K |
| 81001 | <1% | 18,712 | $80K | |
| 71045 | Radiologic examination, chest; single view | <1% | 15,153 | $68K |
| 84484 | <1% | 10,062 | $65K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,778 | $60K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,128 | $57K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,372 | $47K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,820 | $44K |
| 86850 | <1% | 2,192 | $43K | |
| A9270 | Non-covered item or service | <1% | 45,544 | $43K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 379 | $39K |
| 86900 | <1% | 3,688 | $38K | |
| 73610 | <1% | 1,052 | $35K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,662 | $35K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 258 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 26,369 | $30K |
| 87210 | <1% | 3,553 | $30K | |
| 81003 | <1% | 4,359 | $30K | |
| 73562 | <1% | 1,070 | $29K | |
| 82947 | <1% | 1,818 | $28K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,477 | $27K |
| 76801 | <1% | 2,149 | $25K | |
| 73630 | <1% | 1,008 | $24K | |
| 84112 | <1% | 400 | $23K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 773 | $23K |
| 73030 | <1% | 796 | $22K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,143 | $22K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,516 | $21K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 698 | $21K |
| 73130 | <1% | 610 | $20K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,113 | $20K |
| 84702 | <1% | 3,038 | $19K | |
| 85027 | <1% | 12,480 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,277 | $17K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 598 | $17K |
| 93975 | <1% | 1,145 | $17K | |
| 87040 | <1% | 4,683 | $15K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,260 | $15K |
| 85610 | <1% | 7,306 | $15K | |
| 73110 | <1% | 519 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,955 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,596 | $14K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,548 | $14K |
| 85730 | <1% | 5,738 | $13K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,254 | $13K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 612 | $13K |
| 94664 | <1% | 3,857 | $13K | |
| 94760 | <1% | 4,168 | $13K | |
| 87420 | <1% | 1,566 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,574 | $11K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,915 | $11K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,734 | $10K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,617 | $10K |
| 87071 | <1% | 1,186 | $10K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,337 | $10K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 928 | $9K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,523 | $9K |
| 93017 | <1% | 270 | $9K | |
| 83605 | <1% | 4,310 | $9K | |
| 80061 | Lipid panel | <1% | 2,471 | $9K |
| 81025 | <1% | 2,549 | $9K | |
| 93041 | <1% | 10,115 | $8K | |
| G0378 | Hospital observation service, per hour | <1% | 1,052 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,465 | $8K |
| 73502 | <1% | 540 | $8K | |
| 72100 | <1% | 263 | $8K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,220 | $8K |
| 83880 | <1% | 2,615 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,836 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,591 | $7K |
| 76830 | Ultrasound, transvaginal | <1% | 703 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,441 | $6K |
| 93971 | <1% | 752 | $6K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 250 | $6K |
| 96376 | <1% | 2,531 | $6K | |
| 83735 | <1% | 3,431 | $6K | |
| 87077 | <1% | 917 | $6K | |
| 86901 | <1% | 3,642 | $6K | |
| 83690 | <1% | 5,836 | $5K | |
| 87186 | <1% | 3,319 | $5K | |
| 84703 | <1% | 6,693 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 992 | $5K |
| 82962 | <1% | 402 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 127 | $5K |
| 74018 | <1% | 248 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,455 | $4K |
| 87081 | <1% | 3,045 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,330 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,118 | $3K |
| 73080 | <1% | 85 | $3K | |
| 87205 | <1% | 1,047 | $3K | |
| 85379 | <1% | 2,278 | $3K | |
| C1769 | Guide wire | <1% | 151 | $3K |
| 72131 | <1% | 99 | $2K | |
| 82731 | <1% | 26 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,428 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,492 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,661 | $2K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 122 | $2K |
| 93970 | <1% | 58 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,115 | $1K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 48 | $1K |
| 73590 | <1% | 74 | $1K | |
| 85014 | <1% | 86 | $1K | |
| 82247 | <1% | 318 | $984.69 | |
| 87631 | <1% | 37 | $949.83 | |
| 73090 | <1% | 28 | $829.30 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 475 | $822.97 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 446 | $757.78 |
| 97162 | <1% | 12 | $739.63 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 8,768 | $736.36 |
| 86140 | <1% | 1,059 | $727.09 | |
| 87581 | <1% | 8,778 | $678.17 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 533 | $665.19 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 786 | $574.54 |
| 97161 | <1% | 32 | $544.92 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 127 | $527.50 |
| 85055 | <1% | 198 | $498.14 | |
| 85007 | <1% | 2,360 | $453.33 | |
| 82077 | <1% | 622 | $363.51 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 858 | $347.31 |
| 82550 | <1% | 671 | $286.10 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 148 | $281.67 |
| 84439 | <1% | 341 | $276.30 | |
| 71250 | <1% | 42 | $270.69 | |
| 88142 | <1% | 107 | $262.23 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 264 | $240.00 |
| 74022 | <1% | 13 | $239.89 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 102 | $231.20 |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 26 | $202.86 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 56 | $194.60 |
| 87045 | <1% | 14 | $175.21 | |
| 90715 | <1% | 130 | $171.44 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 309 | $168.49 |
| 84481 | <1% | 98 | $155.70 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,235 | $153.06 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 236 | $144.68 |
| 86308 | <1% | 432 | $136.73 | |
| 85018 | <1% | 86 | $122.05 | |
| 82784 | <1% | 22 | $106.08 | |
| 85652 | <1% | 570 | $105.17 | |
| 80179 | <1% | 336 | $89.47 | |
| 82607 | <1% | 286 | $81.59 | |
| 82728 | <1% | 167 | $75.83 | |
| 76937 | <1% | 66 | $70.49 | |
| 29515 | <1% | 29 | $58.60 | |
| 84436 | <1% | 121 | $51.82 | |
| 82248 | <1% | 219 | $44.98 | |
| 85520 | <1% | 81 | $34.40 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 24 | $23.88 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 405 | $23.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 12 | $20.61 |
| 84145 | <1% | 177 | $17.24 | |
| 87340 | <1% | 39 | $16.65 | |
| 83540 | <1% | 242 | $14.42 | |
| 84479 | <1% | 75 | $13.65 | |
| 83550 | <1% | 199 | $11.59 | |
| 82803 | <1% | 109 | $10.11 | |
| 84550 | <1% | 43 | $7.78 | |
| 82570 | <1% | 42 | $6.26 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 531 | $5.39 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 564 | $4.64 |
| 82746 | <1% | 64 | $3.90 | |
| 84156 | <1% | 46 | $3.12 | |
| 86803 | 0% | 14 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 29 | $0.00 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 0% | 29 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 55 | $0.00 |
| 78580 | 0% | 32 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 66 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 43 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 27 | $0.00 |
| 87046 | 0% | 15 | $0.00 | |
| 70486 | 0% | 16 | $0.00 | |
| 86704 | 0% | 15 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 13 | $0.00 |
| 86706 | 0% | 16 | $0.00 | |
| 82553 | 0% | 13 | $0.00 | |
| 99156 | 0% | 22 | $0.00 | |
| 88342 | 0% | 22 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 22 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 438 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 243 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 39 | $0.00 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 0% | 92 | $0.00 |
| 31720 | 0% | 15 | $0.00 | |
| 29125 | 0% | 14 | $0.00 | |
| 85384 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPULIO, KRISTEN (EVP CFO)
| Provider | Location | Paid |
|---|---|---|
| Adventist Healthcare Fort Washington Medical Center INC | Ft Washington, MD | $8.63M |
| Holmes Regional Medical Center, INC | Palm Bay, FL | $7.24M |
| Hospice of Health First INC. | West Melbourne, FL | $4.13M |
| Cape Canaveral Hospital, INC. | Cocoa Beach, FL | $3.66M |
| Viera Hospital INC | Melbourne, FL | $2.04M |
| Blackwell Physicians, LLC | Rockville, MD | $1.94M |
| Adventist Physician Services, INC. | Rockville, MD | $405K |
| Adventist Physician Services, INC. | Takoma Park, MD | $79K |
| Holmes Regional Medical Center, INC. | Melbourne, FL | $25K |
| Adventist Physician Services, INC. | Germantown, MD | $5K |
| Doctors Gi Partnership LTD | Palm Bay, FL | $932.71 |
| Cape Canaveral Hospital, INC. | Melbourne, FL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.